



*Dear **Krabbe Disease and Metachromatic Leukodystrophy** patients, caregivers, families, and advocates*

*We wanted to share an important update with you.*

*As you know, our team at Passage Bio is committed to developing transformative therapies for people with devastating CNS disorders for which there is significant unmet clinical need. To achieve this, our leadership has conducted a thorough review of our business and with this goal in mind, has made the difficult decision to refocus our clinical programs.*

*As part of our refocus in strategy, we will stop further clinical development of PBKR03 for Krabbe disease and PBML04 for Metachromatic Leukodystrophy. We understand this is disappointing for your patient communities and for the healthcare providers caring for individuals with Krabbe and MLD disease.*

*Please know we are fully committed to exploring strategic alternatives to advance the Krabbe and MLD programs. The preclinical data for both programs are promising, and we are dedicated to finding the right partners that will be able to bring these gene therapies to patients in need. We will be sure to keep you updated as to any progress made in this area.*

*If you have any questions, please contact our Patient Services team at [patientservices@passagebio.com](mailto:patientservices@passagebio.com).*

*Thank you,*

*Patient Services Team*